NASD · Healthcare · Health Information Services · USA
Omnicell Inc is a small cap company (market value between $300 million and $2 billion) in the Health Information Services industry.
Omnicell develops healthcare technology solutions for medication management across hospital, outpatient, and retail pharmacy settings. The company offers automated dispensing systems, central pharmacy automation including robotics and IV compounding equipment, and analytics platforms designed to improve medication safety and clinical workflows. Its customer base includes hospitals, health systems, specialty pharmacies, long-term care facilities, and retail pharmacies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Omnicell Inc stock.
Overvalued: intrinsic value $22.67 per share, market price $35.81, margin of safety -57.9% (as of 2026-10-19).
Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $22.67; the price of $35.81 is 58% above that value, and 74% of that value comes from beyond year five.
Leak Score: 57/100 on 11 of 12 signals (Weak Signal).
17 more funds hold it; the full list is part of the paid plan.
All 41 Health Information Services stocks
5 more in this industry show a wider margin of safety.
OMCL is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 9.6% (average of 3 methods) values the shares at $22.67; the price of $35.81 is 58% above that value, and 74% of that value comes from beyond year five.
$22.67 per share (as of the 2026-10-19 close), against a market price of $35.81. That is a margin of safety of -57.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
57 out of 100, which we rate "Weak Signal", on 11 of 12 value investing signals.